Last reviewed · How we verify
TRV027
At a glance
| Generic name | TRV027 |
|---|---|
| Sponsor | Imperial College London |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Novel Experimental COVID-19 Therapies Affecting Host Response (PHASE2, PHASE3)
- RAS and Coagulopathy in COVID19 (EARLY_PHASE1)
- A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure (PHASE2)
- Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure (PHASE1, PHASE2)
- Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRV027 CI brief — competitive landscape report
- TRV027 updates RSS · CI watch RSS
- Imperial College London portfolio CI